Detailseite
Projekt Druckansicht

Nanoskalige Glykopeptid-Konjugate als Melanom-assoziierte vollsynthetische Vakzine für die Antitumor-Immuntherapie (B13)

Fachliche Zuordnung Immunologie
Förderung Förderung seit 2017
Projektkennung Deutsche Forschungsgemeinschaft (DFG) - Projektnummer 213555243
 
TP B13 established a modular vaccine platform using molecular (glyco)peptide building blocks. These carry tumor-associated antigens or immuno-stimulatory components and co-assemble into anisotropic multifunc-tional nanorods. The platform was successfully applied as fully synthetic vaccines against tumor-associated Mucin 1 during the previous funding period and will now be used to develop vaccines against malignant melanoma. Synthetic B-cell epitopes derived from melanoma associated surface protein CSPG4 will be co-presented on the nanorod surface, with T-cell epitopes and immunomodulating agents, and will be evaluated in vivo in terms of tumor-specific antibody induction and therapeutic effect.
DFG-Verfahren Sonderforschungsbereiche
Antragstellende Institution Johannes Gutenberg-Universität Mainz
 
 

Zusatzinformationen

Textvergrößerung und Kontrastanpassung